{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:06:18Z","timestamp":1775433978044,"version":"3.50.1"},"reference-count":48,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Enoxaparin dosing in burn patients is challenging due to physiological changes affecting absorption, distribution and clearance. The objectives of this study are to develop a population pharmacokinetic (PK) model for enoxaparin in burn patients, evaluate target attainment with current equation\u2010based (EQ) dosing and propose an optimized dosing regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Real\u2010world data from 408 burn patients who received enoxaparin for thromboprophylaxis at the University of Utah Burn Center were analysed, comprising 15\u2009517 doses and 1288 antiXa measurements. Only 56% of patients achieved the target antiXa range (0.2\u20130.4\u00a0IU\/mL) approximately 4\u2009h after the third dose. A one\u2010compartment PK model with first\u2010order absorption and elimination best fit the data, with estimated apparent clearance (CL\/F), volume of distribution (Vc\/F) and absorption rate constant at 1.56\u2009L\/h, 22.1\u00a0L and 1.10\u20091\/h, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Total burn surface area (TBSA) and body weight significantly influenced clearance and distribution, while glomerular filtration rate had no notable impact. Simulations showed that EQ dosing failed to achieve target levels after the first dose in ~40% of patients, while the proposed model\u2010based regimen improved target attainment by more than 70%. This study underscores the limitations of EQ dosing, and patients with larger TBSA or higher body weight particularly benefited from the proposed regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A population PK model of enoxaparin was developed in burn patients using real\u2010world data. Model\u2010informed dosing improved early prophylactic target attainment compared with EQ dosing, providing a practical strategy for optimizing enoxaparin prophylaxis in this high\u2010risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70347","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:42:08Z","timestamp":1763970128000},"page":"1126-1136","source":"Crossref","is-referenced-by-count":0,"title":["A real\u2010world data\u2010driven approach to optimizing enoxaparin dosing in burn patients"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3315-780X","authenticated-orcid":false,"given":"Babajide","family":"Shenkoya","sequence":"first","affiliation":[{"name":"Center for Translational Medicine, Department of Pharmacy Practice University of Maryland School of Pharmacy  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-9054","authenticated-orcid":false,"given":"Venkata","family":"Yellepeddi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Spencer Fox Eccles School of Medicine University of Utah  Salt Lake City Utah USA"},{"name":"Department of Molecular Pharmaceutics, College of Pharmacy University of Utah  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1271-476X","authenticated-orcid":false,"given":"Ann Marie B.","family":"Prazak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services University of Utah Health  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2881-9870","authenticated-orcid":false,"given":"Mathangi","family":"Gopalakrishnan","sequence":"additional","affiliation":[{"name":"Center for Translational Medicine, Department of Pharmacy Practice University of Maryland School of Pharmacy  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"WHO.Global burns: factsheet.2023.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/burns"},{"key":"e_1_2_10_3_1","volume-title":"StatPearls","author":"Schaefer TJ","year":"2024"},{"issue":"1","key":"e_1_2_10_4_1","first-page":"19","article-title":"Estimation of Total body surface area burned: a comparison between burn unit and referring facilities","volume":"36","author":"Ho HL","year":"2023","journal-title":"Ann Burns Fire Disasters"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010020\u20100145\u20105"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2008.07323.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100034\u20101398380"},{"key":"e_1_2_10_8_1","first-page":"233","article-title":"Maladie thromboembolique veineuse chez le br\u00fbl\u00e9: incidence et facteurs de risque","volume":"37","author":"Khalifa HB","year":"2024","journal-title":"Ann Burns Fire Disasters"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/irae036.119"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/BCR.0b013e318204b2ff"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102005\u201004\u20101546"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200342120\u201000003"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2015.5844"},{"key":"e_1_2_10_14_1","unstructured":"Sanofi\u2010Aventis.Lovenox (enoxaparin sodium) [package insert].1993."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010199529010\u201000003"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.3.319"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200847100\u201000002"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.17.1793.52344"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/iry006.034"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000002830"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2020.12.011"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100038\u20101651032"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2019.02.011"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e3182788fa7"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e31823070f9"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/BCR.0b013e318204b346"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/irab039"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccm.0000458569.26268.90"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v11i6.3960"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/BCR.0b013e3182a2a855"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2021.07.010"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102125.2003.01849.x"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2010.03.012"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102125.2003.01904.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000435"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003198"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538\u20107836.2010.03964.x"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010024\u201001388\u2010x"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13543"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181961bff"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010023\u201001213\u2010x"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/irad045.267"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.09.019"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054\u2010016\u20101208\u20106"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.6001\/actamedica.v26i1.3954"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.5.3372"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60020258"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70347","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70347","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T23:41:49Z","timestamp":1775432509000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/bcp.70347"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70347","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]}}}